Healthcare / Drug Manufacturers - GeneralUpdated 2026-05-10 22:07 UTC

LON/GSK stock hub

LON/GSK has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

LON/GSKis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

73.6B

London Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

LON/GSK

In the news

Latest news · LON/GSK

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E10.1

P25 12.9P50 16.9P75 23.5

Trailing P/E13

P25 15.9P50 22.9P75 35.8

ROE40.9

P25 -54.2P50 2.1P75 13.7

ROIC26.7

P25 -38.1P50 3.3P75 11.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All LON/GSK market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

249

Groups with data

Currency

GBP

Showing 249 of 249 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United Kingdom
Country code	UK
Employees	66,841
Employees Change	-1,788%
Employees Change Percent	-2.61
Enterprise value	GBX 88.8B
Exchange	London Stock Exchange
Financial currency	GBP
First seen	2026-05-10
Industry	Drug Manufacturers - General
Isin	GB00BN7SWP63
Last refreshed	2026-05-10
Market cap	GBX 73.6B
Price	GBX 1,843
Price currency	GBX
Rev Per Employee	490,417.56x
Sector	Healthcare
Sic	2834
Symbol	lon/GSK
Website	https://www.gsk.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	7.92%
EV Earnings	15.24x
EV/EBIT	8.97x
EV/EBITDA	7.63x
EV/FCF	13.93x
EV/Sales	2.71x
FCF yield	8.67%
Forward P/E	10.08x
P/B ratio	4.22x
P/E ratio	12.98x
P/S ratio	2.24x
PE Ratio10 Y	90.22x
PE Ratio3 Y	14.7x
PE Ratio5 Y	13.73x
PEG ratio	1.75x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	30.22%
EBITDA Margin	34.88%
FCF margin	19.45%
Gross margin	72.87%
Gross Profit	GBX 23.9B
Gross Profit Growth	5.34%
Gross Profit Growth Q	2.97%
Gross Profit Growth3 Y	5.29%
Gross Profit Growth5 Y	3.18%
Net Income	GBX 5.8B
Net Income Growth	84.87%
Net Income Growth Q	6.96%
Net Income Growth Quarters	6%
Net Income Growth Years	1%
Net Income Growth3 Y	-26.44%
Net Income Growth5 Y	2.09%
Pretax Margin	22.69%
Profit Margin	17.78%
Profit Per Employee	GBX 87,207
Profitable Years	41
ROA	10.02
Roa5y	7.23
ROCE	24.49
ROE	40.91
Roe5y	32.1
ROIC	26.7
Roic5y	22.54

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	7.36%
Cagr15y	7.36%
Cagr1y	39.11%
Cagr20y	5.92%
Cagr3y	12.41%
Cagr5y	10.72%
Div CAGR10	-6.05%
Div CAGR3	5.08%
Div CAGR5	-7.7%
EPS Growth	86.56
EPS Growth Q	8.4
EPS Growth Quarters	6
EPS Growth Years	1
EPS Growth3 Y	-26.53
EPS Growth5 Y	1.74
FCF Growth	18.47%
FCF Growth Q	-1.81%
FCF Growth3 Y	19.56%
FCF Growth5 Y	-0.62%
OCF Growth	14.78%
OCF Growth Q	-0.35%
OCF Growth10 Y	11.09%
OCF Growth3 Y	16.34%
OCF Growth5 Y	-0.18%
Revenue Growth	3.97x
Revenue Growth Q	1.5x
Revenue Growth Quarters	6x
Revenue Growth Years	4x
Revenue Growth3 Y	4.07x
Revenue Growth5 Y	1.68x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	GBX 0.53
Assets	GBX 62.9B
Cash	GBX 3.4B
Current Assets	GBX 17.8B
Current Liabilities	GBX 22.4B
Debt	GBX 19.1B
Debt EBITDA	GBX 1.64
Debt Equity	GBX 1.1
Debt FCF	GBX 3
Equity	GBX 17.4B
Interest Coverage	14.94
Liabilities	GBX 45.4B
Long Term Assets	GBX 45.1B
Long Term Liabilities	GBX 23B
Net Cash	GBX -15.7B
Net Cash By Market Cap	GBX -21.3
Net Debt EBITDA	GBX 1.37
Net Debt Equity	GBX 0.9
Net Debt FCF	GBX 2.46
Tangible Book Value	GBX -7.6B
Tangible Book Value Per Share	GBX -1.88
WACC	5.29

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	0.79
Inventory Turnover	1.46
Net Working Capital	GBX -3.1B
Quick ratio	0.51
Working Capital	GBX -4.7B
Working Capital Turnover	GBX -8.84

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	1.13%
Dividend Growth	8.06%
Dividend Growth Years	2%
Dividend per share	GBX 0.72
Dividend Years	35
Dividend Yield	3.91%
Ex Div Date	2026-05-14
Last Dividend	GBX 0.17
Payout Frequency	Quarterly
Payout Ratio	44.52%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	103.31%
1Y total return	39.08%
200-day SMA	1,799.1
3Y total return	42.04%
50-day SMA	2,053.1
50-day SMA vs 200-day SMA	50over200
5Y total return	66.39%
All Time High	3,408.2
All Time High Change	-45.92%
All Time High Date	2022-06-14
All Time Low	1,225
All Time Low Change	50.45%
All Time Low Date	2003-03-12
ATR	49.06
Beta	0.3
Beta1y	0.81
Beta2y	0.67
Ch YTD	1.01
High	1,857.5
High52	2,282
High52 Date	2026-02-18
High52ch	-19.24%
Low	1,831.5
Low52	1,288.6
Low52 Date	2025-08-21
Low52ch	43.02%
Ma50ch	-10.23%
Price vs 200-day SMA	2.44%
RSI	27.08
RSI Monthly	56.22
RSI Weekly	46.08
Sharpe ratio	1.29x
Sortino ratio	2.36
Total Return	5.03%
Tr YTD	1.82
Tr15y	190.11%
Tr1m	-12.07%
Tr1w	-3.05%
Tr3m	-15.48%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	GBX 9.9B
Operating Income Growth	59.89
Operating Income Growth Q	19.83
Operating Income Growth3 Y	10.08
Operating Income Growth5 Y	6.55
Operating margin	30.22

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	3,864,337,078%
Net Borrowing	533,000,000
Shares Insiders	0.07%
Shares Institutions	86.82%
Shares Out	3,991,945,533
Shares Qo Q	-0.29%
Shares Yo Y	-1.13%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	GBX 6B
Average Volume	6,646,650.7x
Bv Per Share	4.44
CAPEX	GBX -1.4B
Ch10y	2.39
Ch15y	12.04
Ch1m	-12.07
Ch1w	-3.05
Ch1y	33.65
Ch20y	-4.32
Ch3m	-16.15
Ch3y	26.03
Ch5y	8.76
Ch6m	4.21
Change	-0.83%
Change From Open	-0.65
Close	1,858.5
Days Gap	-0.19
Depreciation Amortization	1,528,000,000
Dollar Volume	11,258,571,847
Earnings Date	2026-04-29
EBIT	GBX 9.9B
EBITDA	GBX 11.4B
EPS	GBX 1.42
F Score	7
FCF	GBX 6.4B
FCF EV Yield	7.18x
FCF Per Share	GBX 1.6
Financing CF	-4,271,000,000
Fiscal Year End	December
Founded	1,715
Goodwill	7,287,000,000
Graham Number	1197.437
Graham Upside	-35.03
Income Tax	GBX 1.1B
Investing CF	-4,555,000,000
Is Primary Listing	1
Last Earnings Date	2026-04-29
Last Report Date	2026-03-31
Last Split Date	2022-07-19
Last Split Type	Reverse
Lynch Fair Value	GBX 730
Lynch Upside	-60.39
Ma150	1,911.4
Ma150ch	-3.58%
Ma20	2,027.8
Ma20ch	-9.11%
Net CF	-1,095,000,000
Next Earnings Date	2026-07-29
Open	1,855
P FCF Ratio	11.54
P OCF Ratio	9.51
Payment Date	2026-07-09
Position In Range	44.23
Ppne	10,038,000,000
Price Date	2026-05-08
Price EBITDA	GBX 6.44
Relative Volume	0.92x
Revenue	32,780,000,000x
SBC By Revenue	1.14x
Share Based Comp	374,000,000
Tax By Revenue	3.3x
Tax Rate	14.54%
Tr20y	215.94%
Tr6m	5.98%
Volume	6,108,829
Z Score	2.09

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

LON/GSK dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+3.9%

$0.72 annual per share

Payout ratio

+44.5%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

-7.7%

2 consecutive years of growth

Total shareholder yield

+5.0%

Next ex-dividend date: 2026-05-14

Performance

LON/GSK stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns LON/GSK?

Insider, institutional, and short-interest positioning.

Institutional ownership

+86.8%

Share of float held by funds and institutions

Insider ownership

+0.1%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

-1.1%

Negative means the company is buying back shares.

Technical

LON/GSK momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

27.1

Below 30: short-term oversold

Price vs 200-day MA

+2.4%

50/200-day relationship not available

Beta (5Y)

0.30

Less volatile than the market

Sharpe ratio

1.28

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About LON/GSK

Hub-level FAQ points readers to the deeper analysis pages.

What is the current lon/GSK stock rating?

lon/GSK is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full lon/GSK analysis?

The full report lives at /stocks/lon/GSK/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for lon/GSK?

The latest report frames lon/GSK around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the lon/GSK page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.